Literature DB >> 2508202

Rapid radiometric method for pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

M Salfinger1, L B Reller, B Demchuk, Z T Johnson.   

Abstract

Pyrazinamide (PZA) is one of the most important drugs in modern chemotherapy of tuberculosis. Since PZA is active only at an acid pH, testing the susceptibility of Mycobacterium tuberculosis to PZA is difficult and timeconsuming. Therefore, we evaluated the BACTEC system for rapid testing of PZA susceptibility at pH 6. A total of 91 M. tuberculosis strains and 2 different strains of M. bovis BCG were screened for susceptibility to PZA. Each strain was tested in special 7H12 broth supplemented with polyoxyethylene stearate containing 25, 50 and 100 micrograms PZA/ml. Strains resistant to 100 micrograms/ml were retested against 25-100 micrograms/ml and at an extended range of PZA concentrations from 200-6,400 micrograms/ml. The MIC was determined with all strains within 4-20 (mean 7) days. Of the 77 susceptible strains, based on the pyrazinamidase test, MIC were less than or equal to 25 micrograms/ml for 34 strains, 50 for 38 and 100 for 2 strains. Three pyrazinamidase-positive strains had still higher MIC, 1 at 800 and 2 at 3,200 micrograms/ml. PZA-resistant strains had MIC of 800 or greater. Monoresistance to PZA has not been detected to date. The clear bimodal distribution of MIC in this method could enable the routine clinical microbiology laboratory to perform PZA susceptibility testing as easily as the 4 drugs now tested in the BACTEC system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2508202     DOI: 10.1016/0923-2508(89)90022-3

Source DB:  PubMed          Journal:  Res Microbiol        ISSN: 0923-2508            Impact factor:   3.992


  11 in total

1.  Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors:  G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

Review 2.  Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses.

Authors:  Kwok Chiu Chang; Wing Wai Yew; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

3.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.

Authors:  Gaby E Pfyffer; Frantiska Palicova; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

4.  Growth inhibition of Mycobacterium tuberculosis by polyoxyethylene stearate present in the BACTEC pyrazinamide susceptibility test.

Authors:  M A Miller; L Thibert; F Desjardins; S H Siddiqi; A Dascal
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

5.  Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis.

Authors:  G P Morlock; J T Crawford; W R Butler; S E Brim; D Sikes; G H Mazurek; C L Woodley; R C Cooksey
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Intrapulmonary concentrations of pyrazinamide.

Authors:  J E Conte; J A Golden; S Duncan; E McKenna; E Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Sequencing of the pncA gene in members of the Mycobacterium tuberculosis complex has important diagnostic applications: Identification of a species-specific pncA mutation in "Mycobacterium canettii" and the reliable and rapid predictor of pyrazinamide resistance.

Authors:  Akos Somoskovi; Jillian Dormandy; Linda M Parsons; Michel Kaswa; Khye Seng Goh; Nalin Rastogi; Max Salfinger
Journal:  J Clin Microbiol       Date:  2006-11-29       Impact factor: 5.948

8.  Detection by denaturing gradient gel electrophoresis of pncA mutations associated with pyrazinamide resistance in Mycobacterium tuberculosis isolates from the United States-Mexico border region.

Authors:  Mark T McCammon; John S Gillette; Derek P Thomas; Srinivas V Ramaswamy; Ishmael I Rosas; Edward A Graviss; Jan Vijg; Teresa N Quitugua
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

9.  Multicenter evaluation of a nonweekend reading schedule for radiometric pyrazinamide susceptibility testing of Mycobacterium tuberculosis.

Authors:  B Madison; W Gross; I George; A Sloutsky; G Washabaugh; B Robinson-Dunn; H Lipman; B Metchock; G Mazurek; J Ridderhof
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis.

Authors:  Linda M Parsons; Roland Brosch; Stewart T Cole; Akos Somoskövi; Arthur Loder; Gisela Bretzel; Dick Van Soolingen; Yvonne M Hale; Max Salfinger
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.